Allogene Therapeutics Director Shows Long-term Commitment with Major Option Grant

Rhea-AI Filing Summary

Insider Trading Alert: Allogene Therapeutics (ALLO) Director Vicki L. Sato received a significant stock option grant on June 18, 2025. The transaction details reveal:

• Granted 144,400 stock options to purchase common stock
• Exercise price set at $1.29 per share
• Options expire on June 18, 2035
• Vesting schedule: Equal monthly installments over 12 months

This Form 4 filing indicates a standard director compensation package through equity incentives. The relatively low exercise price and extended 10-year expiration term suggest a long-term alignment with shareholder interests. The monthly vesting schedule encourages continued service on the board. The transaction was executed directly, with no indirect ownership reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SATO VICKI L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	144,400	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 144,400 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.29	06/18/2025		A		144,400		(1)	06/18/2035	Common Stock	144,400	$0	144,400	D

Explanation of Responses:

1. Vesting in 12 equal monthly installments.

Remarks:

Exhibits: Power of Attorney

	/s/Earl Douglas, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did ALLO director Vicki Sato receive on June 18, 2025?

Director Vicki Sato received 144,400 stock options with an exercise price of $1.29 per share. The options were granted on June 18, 2025, and will expire on June 18, 2035. These options vest in 12 equal monthly installments.

What is the exercise price of ALLO's stock options granted to Vicki Sato in June 2025?

The stock options granted to Vicki Sato have an exercise price of $1.29 per share.

When do Vicki Sato's ALLO stock options expire?

The stock options granted to Vicki Sato on June 18, 2025, will expire on June 18, 2035, giving them a 10-year term.

What is the vesting schedule for ALLO director Vicki Sato's June 2025 stock options?

According to the Form 4 filing, the stock options vest in 12 equal monthly installments from the grant date of June 18, 2025.

What position does Vicki Sato hold at ALLO?

According to the Form 4 filing, Vicki Sato serves as a Director of Allogene Therapeutics, Inc. (ALLO), as indicated by the 'X' marked in the Director box under the relationship section.